Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuroone Medical Technologies (NMTC) EPS (Weighted Average and Diluted) (2021 - 2025)

Neuroone Medical Technologies' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.03 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 150.0% year-over-year to -$0.03; the TTM value through Dec 2025 reached -$0.17, up 34.62%, while the annual FY2025 figure was -$0.09, 80.43% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.03 in Q4 2025 per NMTC's latest filing, up from -$0.04 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.06 in Q4 2024 to a low of -$0.25 in Q3 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.13, with a median of -$0.13 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 142.86% in 2024, then crashed 150.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.18 in 2021, then skyrocketed by 41.41% to -$0.11 in 2022, then crashed by 31.14% to -$0.14 in 2023, then skyrocketed by 142.86% to $0.06 in 2024, then plummeted by 150.0% to -$0.03 in 2025.
  • Per Business Quant, the three most recent readings for NMTC's EPS (Weighted Average and Diluted) are -$0.03 (Q4 2025), -$0.04 (Q3 2025), and -$0.03 (Q2 2025).